Assemble drug-delivery combination devices (syringe/autoinjector/dosing device)
Bayer markets engineered drug-delivery devices such as the Eylea 8 mg OcuClick pre-filled syringe with a mechanical dose-setting mechanism, plus other injectable/contraceptive delivery formats. Final assembly of such combination products involves inserting the filled primary container into a housing, fitting plungers/rods, attaching needle shields or caps, and snapping/press-fitting plastic sub-components to tight tolerances so the dosing mechanism functions reliably. The parts are a mix of rigid plastics, glass, and elastomers with low dimensional tolerance for a mechanism that must deliver a precise dose every time. It is hard for a robot because over-force cracks glass or deforms plastic snap features, while under-force leaves a partially engaged closure that passes a visual check but fails in the field. Volumes track the injectable franchises and the new Turku contraceptive plant being built around automation and robotics. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionBayer markets engineered drug-delivery devices such as the Eylea 8 mg OcuClick pre-filled syringe with a mechanical dose-setting mechanism, plus other injectable/contraceptive delivery formats. Final assembly of such combination products involves inserting the filled primary container into a housing, fitting plungers/rods, attaching needle shields or caps, and snapping/press-fitting plastic sub-components to tight tolerances so the dosing mechanism functions reliably. The parts are a mix of rigid plastics, glass, and elastomers with low dimensional tolerance for a mechanism that must deliver a precise dose every time. It is hard for a robot because over-force cracks glass or deforms plastic snap features, while under-force leaves a partially engaged closure that passes a visual check but fails in the field. Volumes track the injectable franchises and the new Turku contraceptive plant being built around automation and robotics.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.